最後更新 2024-05-14 07:31:50 (UTC+8)

基本分析

透過季節調整季營收,判斷美股整體趨勢,但注意股價有時候領先基本面的數據,應搭配其他領先指標判斷。

季營收趨勢 tooltip

季節調整季營收
季增率

32.4%


截至2024-03-31

基本資料

個股的基本資料,以及所屬的類股和產業。

公司介紹

業務介紹

Organon & Co.是一家醫療保健公司,通過一系列處方療法在美國和國際市場開發和提供健康解決方案。其婦科產品組合包括避孕和生育品牌,如長效可逆避孕劑Nexplanon/Implanon。該公司的生物仿製藥產品組合包括三種免疫學產品,如Brenzys、Renflexis和Hadlima,以及兩種腫瘤學產品,包括Ontruzant和Aybintio。此外,它還提供心血管產品,包括多種膽固醇調節藥物,如Zetia、Ezetrol、Vytorin、Inegy、Rosuzet和Zocor品牌;用於治療高血壓的Cozaar和Hyzaar;呼吸產品,用於控制和預防哮喘引起的症狀,品牌有Singulair、Dulera、Zenhale和Asmanex;以及用於治療季節性過敏性鼻炎的Singulair、Nasonex、Clarinex和Aerius。此外,該公司還提供皮膚科產品,品牌有Diprosone和Elocon;骨骼健康產品組合,包括Fosamax品牌;非阿片類疼痛管理產品,品牌有Arcoxia、Diprospan和Celestone;用於治療症狀性良性前列腺增生的Proscar;以及用於治療男性型脫髮的Propecia。該公司主要將產品銷售給藥品批發商和零售商、醫院和政府機構,以及管理醫療保健提供者,如健康維護組織、藥品效益管理者和其他機構。Organon & Co.成立於2020年,總部位於新澤西州澤西市。

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

所屬產業

所屬類股
Healthcare
所屬產業
Drug Manufacturers - General

警語

1. 資料僅供參考,不做任何獲利保證及特定股票與點位推薦建議。

2. 資料並不完整,需要完整資料請至相關網站索取。

3. 任何股市數據分析皆存在倖存者偏差。

warning